Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors

Nuvectis Pharma, Inc.

Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.
Sanchez served as VP of Corp Comm & IR at Intra-Cellular Therapies, acquired by J&J for $14.6B in April 2025.
He brings 30+ years experience in biotech, capital markets, and clinical medicine.
Company plans to start Phase 1b program for NXP900, a precision oncology drug candidate.
No arrangements or family relationships; no material transactions per Item 404(a).

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.